A clinical-stage biopharmaceutical company developing oral therapies for bradykinin-mediated angioedema, led by deucrictibant for hereditary angioedema (HAE) as both on-demand and prophylactic treatment options.
A clinical-stage biopharmaceutical company developing oral therapies for bradykinin-mediated angioedema, led by deucrictibant for hereditary angioedema (HAE) as both on-demand and prophylactic treatment options.
